Precision Medicine

Precision Medicine

Targeted Oncology presents Precision Medicine, a video series featuring oncology experts discussing how to use a more customized approach when treating patients with cancer.


Bispecific Antibodies for Follicular Lymphoma

December 2nd 2022

Two expert hematologist-oncologists review treatment options for patients with follicular lymphoma and consider how to select the appropriate therapy based on patient and disease factors.

Targeted Treatments for Myeloproliferative Neoplasms

October 28th 2022

Expert hematologist-oncologists review treatment options for patients with myeloproliferative neoplasms and consider patient and disease factors that inform the selection of optimal therapy.

Potential Role of Magrolimab in the Treatment of Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

September 29th 2022

Hetty Carraway, MD, and Eytan M. Stein, MD, discuss treatment options for patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia, and how to select the best treatment regimen based on patient and disease factors.

Evidence-Based Strategies for Selecting the Appropriate Frontline Therapy in Advanced RCC

September 16th 2022

Expert hematologist/oncologists highlight recent advances in the treatment of advanced RCC and consider their impact on clinical practice.

Frontline Treatment of Acute Myeloid Leukemia

June 30th 2022

Hetty Carraway, MD, and Eytan Stein, MD, discuss the frontline treatment options for patients with AML and how to select the best treatment approach based on patient and disease factors.

BCL-2 Family Proteins as Therapeutic Targets in Multiple Myeloma

April 6th 2022

Shaji Kumar, MD, and Jonathan Kaufman, MD, discuss the role of BCL-2 proteins in multiple myeloma treatment and recent safety and efficacy data on BCL-2 inhibitors.

ALK Gene Rearrangements As A Therapeutic Target in Non-small Cell Lung Cancer

November 23rd 2021

Two leading experts in lung cancer provide insights on therapies targeting ALK mutations patients with non-small-cell lung cancer.

CD19 as a Target in the Treatment of DLBCL

October 29th 2021

Reactions to recent data on the integration of CD19-targeted therapies into the treatment of patients with diffuse large B-cell lymphoma.

The Changing Landscape of Chronic Graft vs. Host Disease

October 8th 2021

John DiPersio, MD, PhD, and Michael Bishop, MD, review the use of JAK inhibitors in chronic GvHD and practical considerations for disease management.

Bruton’s Tyrosine Kinase in B-Cell Malignancies: Advances in Targeted Therapy

September 30th 2021

Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, discuss and compare BTK inhibitors used as targeted therapy for B-cell malignancies, taking into account data from clinical trials and their personal experiences.